Merck & Co. shares have surged 72% since the last bullish call, outperforming the benchmark's 15% gain. Despite strong performance, the stock now trades at a high forward P/E ratio of 14x for 15 months ahead, with elevated earnings expectations for FY2027 limiting upside potential. The analyst has downgraded Merck from Strong Buy to Hold, suggesting investors wait for fundamentals to improve before buying more. Merck remains a defensive, dividend-yielding stock, but its near-term growth prospects are constrained by current valuation and earnings forecasts.
Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition off...
Merck & Co. surged to all-time highs following positive Phase 3 trial results of its melanoma vaccine developed with Moderna. The company maintains a Buy rating due to strong growth in oncology, solid free cash flow, and potential for further stock g...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
Moderna's stock jumped 93% following the announcement that its Phase 3 melanoma trial, conducted with Merck, met its primary endpoint by significantly improving recurrence-free survival when combined with Merck's Keytruda. This marks the first positi...
Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phas...
